Incyclix Bio announces new additions to the Board
pharmafile | April 22, 2026 | Appointment | | Incyclix Bio
Incyclix Bio has announced that it has raised $5m in additional funds for its Series B financing from new investor Hatteras Venture Partners. As part of the financing, Hatteras partner Kseniya Simpson will join the Company’s board of directors and Hatteras general partner Christy Shaffer will join as a board observer.
“We are encouraged by Hatteras’s strong enthusiasm for our CDK2 programme and their support in advancing INX-315 toward meaningful clinical outcomes,” said Patrick Roberts, CEO and Co-Founder of Incyclix Bio. “Additionally, we’re pleased to welcome Kseniya and Christy to our board and look forward to working with them during this pivotal time of growth for Incyclix.”
The additional funds will support of the clinical development of the Company’s lead compound INX-315, a novel, potent and selective CDK2 inhibitor, for the treatment of advanced and metastatic breast and ovarian cancer. Hatteras joins other top-tier investors who participated in the Series B round, including Boxer Capital, RA Capital Management, Eshelman Ventures, Eli Lilly and Company, Pharmacosmos and Cape Fear BioCapital.
“CDK2 inhibition represents an exciting opportunity to address unmet need that remains in breast and ovarian cancer treatment,” said Kseniya Simpson. “We believe in Incyclix’s highly experienced team and their capabilities to bring a best-in-class treatment option to patients with advanced and resistant cancer.”
The phase 1/2 open-label, dose-escalation, combination and dose-expansion clinical trial of INX- 315 is ongoing.
Incyclix Bio is a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for the treatment of advanced and resistant cancer.
